Chronic pain is a common neurological disease involving lasting, multifaceted maladaptations ranging from gene modulation to synaptic dysfunction and emotional disorders. Sustained pathological stimuli in many diseases alter the output activities of certain genes through epigenetic modifications, but it is unclear how epigenetic mechanisms operate in the development of chronic pain. We show here that in the rat brainstem nucleus raphe magnus, which is important for central mechanisms of chronic pain, persistent inflammatory and neuropathic pain epigenetically suppresses Gad2 (encoding glutamic acid decarboxylase 65 (GAD65)) transcription through histone deacetylase (HDAC)-mediated histone hypoacetylation, resulting in impaired g-aminobutyric acid (GABA) synaptic inhibition. Gad2 knockout mice showed sensitized pain behavior and impaired GABA synaptic function in their brainstem neurons. In wild-type but not Gad2 knockout mice, HDAC inhibitors strongly increased GAD65 activity, restored GABA synaptic function and relieved sensitized pain behavior. These findings suggest GAD65 and HDACs as potential therapeutic targets in an epigenetic approach to the treatment of chronic pain.
a r t i c l e s Environmental factors and pathological conditions can result in the alteration of transcription of many genes through modifications of chromatin structure, including DNA methylation and histone acetylation, resulting in stable phenotypes 1, 2 . Chromatin remodeling dynamically modulates, either positively or negatively, the transcriptional activity of target genes 3 . Histone acetylation increases gene transcription by decondensing chromatin structure, which allows increased accessibility of transcriptional machinery to DNA for transcriptional activation 4 . Epigenetic mechanisms are implicated in adaptive responses to many neurological disorders in which persistent neurochemical stimuli are present 5, 6 . For example, histone acetylation crucially regulates synaptic plasticity and memory formation 7 , and drugs of abuse alter chromatin structure through histone acetylation and phosphorylation, leading to maladaptive changes that cause drug addiction [8] [9] [10] .
Chronic pain is a neurological disease caused by nerve injury and persistent tissue inflammation under various pathological conditions such as cancer and neurodegenerative diseases 11 . Distinct from acute pain, chronic pain could induce long-term synaptic and cellular maladaptive changes, involve dynamic memory processes and cause characteristic emotional disorders including depression, stress and anxiety [11] [12] [13] [14] . The molecular mechanisms underlying chronic pain development remain poorly understood. The characteristics of chronic pain are strongly suggestive of epigenetic modulations. Evidence is emerging in animal pain models that show antinociceptive effects of HDAC inhibitors 15, 16 and epigenetic regulation of C-fiber dysfunction in hypoesthesia 17 . However, how epigenetic mechanisms operate and what the target genes are in chronic pain development are largely unknown. In this study, we explored persistent pain-induced histone modifications in mouse and rat models of inflammatory and neuropathic pain. Whereas spinal adaptive mechanisms are important in chronic pain, our study focused on the brainstem nucleus raphe magnus (NRM), a crucial supraspinal site for maintenance of pain hypersensitivity in behavioral states of chronic pain 18, 19 .
RESULTS

Inflammatory pain increases global histone acetylation
We first examined global histone acetylation levels in rats with persistent inflammatory pain induced by complete Freund's adjuvant (CFA) 20 . CFA induced persistent pain sensitization (hyperalgesia) ( Fig. 1a ). Sampling NRM tissues at different time points (4 h, 12 h, 1 d, 3 d and 6 d after CFA injection), we found that global histone H3 acetylation was unchanged until 1 d after injection, from which point it showed a continued increase for the following 6 d (Fig. 1b,c) . Total H3 protein levels were unchanged during this period. In tissues taken at 3 d after injection (representing persistent pain), both histone H3 and H4 acetylation levels were increased but the total H4 protein level was not ( Fig. 1d-f ). We obtained similar results by ELISA for H3 acetylation at 3 d after injection (171.4% ± 34.1% increase (mean ± s.e.m.), n = 7, P < 0.05). These results suggest that persistent pain (lasting for >1 d), but not acute pain (lasting for hours), involves global histone hyperacetylation in the NRM.
Persistent pain decreases GABAergic synaptic function
Chronic pain is presumably caused partly by sustained activation of descending pain-facilitatory pathways from NRM 18 . This neuronal hyperactivation could result from loss of inhibitory GABA functions in the NRM. In NRM neurons from CFA-injected rats, we found that the slope of the input-output curve for GABAergic inhibitory postsynaptic currents (IPSCs) was similar to that in controls at 4 h after a r t i c l e s nature medicine VOLUME 17 | NUMBER 11 | NOVEMBER 2011 1 4 4 9 injection (acute pain) but decreased at 3 d after injection (persistent pain) ( Fig. 2a,b) . We saw no difference in the IPSC slopes from hippocampal neurons ( Fig. 2c) .
For the synaptic site of this decrease, we found that the pairedpulse ratio, which is inversely related to presynaptic neurotransmitter release 21, 22 , was unchanged at 4 h but increased at 3 d after injection ( Fig. 2d-f ), and miniature IPSC (mIPSC) frequency, but not amplitude, was reduced at 3 d but not at 4 h after injection ( Fig. 2g-j) , indicating decreased presynaptic GABA release. Thus, persistent pain decreases presynaptic function of GABA synapses in NRM neurons. Figure 1 Persistent inflammatory pain induces time-dependent hyperacetylation of histones H3 and H4. (a) Time course for the development of persistent pain sensitization induced by CFA and for saline controls, as measured by the paw-withdrawal test (n = 6 rats in each group). (b,c) Western blots (b) and summarized data (c) (n = 5-9 rats for each group) of global acetylated histone H3 (AcH3) and total H3 proteins, normalized to β-actin, in tissues of rat NRM taken at various time points after CFA injection. (d) Western blots of AcH3 and acetylated histone H4 (AcH4) 3 d after CFA injection. (e,f) Western blots (e) and summarized results (f) (n = 7 rats for each group) of AcH4 and total H4 after CFA injection. Data are expressed as mean ± s.e.m. *P < 0.05, **P < 0.01. BL, baseline; sal, saline. a r t i c l e s Persistent pain epigenetically reduces GAD65 expression GAD65 is a GABA synthetic enzyme that preferentially synthesizes GABA in the synaptic terminal for vesicle release, whereas GAD67 preferentially synthesizes cytoplasmic GABA 23, 24 . We used chromatin immunoprecipitation (ChIP) assays to determine H3 acetylation levels in Gad2 promoter regions under pain conditions. We found that H3 acetylation in the region of −646 to −484 bp upstream of the transcription start site (TSS) of Gad2 was reduced in rats at 3 d after CFA injection but not at 4 h afterward ( Fig. 3a) . Systemic treatment with the HDAC inhibitors trichostatin A (TsA) or suberoylanilide hydroxamic acid (SAHA), which increase histone acetylation nonselectively 25 , increased the pain-reduced H3 acetylation level in the Gad2 promoter region and increased global H3 acetylation in the NRM of saline-and CFA-injected rats ( Fig. 3a-c) . At 3 d after CFA injection, acetylated H3 was also reduced in the Gad2 promoter region at −285 to −153 bp upstream of the TSS but not in regions <150 bp or >2 kb upstream ( Fig. 3d) .
We determined the relative levels of HDAC1 and HDAC2 (class I HDACs) and HDAC4 and HDAC5 (activity-dependent class II HDACs) 26, 27 present on the Gad2 promoter in NRM chromatin preparations from rats at 3 d after CFA injection and found chromatin-associated HDAC1, HDAC2 and HDAC4 marks, but not HDAC5 marks, in the Gad2 promoter ( Fig. 3e) . Additionally, the GAD65 mRNA level was decreased, and so was the GAD65 protein level ( Fig. 4a-c) . We saw no change in GAD65 expression 4 h after CFA injection. These reductions in GAD65 transcriptional and translational activities were completely reversed by treatment with TsA ( Fig. 4a-c) . TsA also increased GAD65 protein abundance in control rats to a lesser extent ( Fig. 4d ), suggesting a global TsA effect. Persistent pain decreased co-localization of GAD65 and terminal protein synapsin I by 46% ± 10% (mean ± s.e.m.), and the co-localization was increased approximately twofold by TsA in NRM neurons (Fig. 4e) . These results indicate that CFA-induced persistent hyperalgesia epigenetically suppresses Gad2 transcription in the NRM and that HDAC-inhibitor-induced global histone hyperacetylation can overwhelm this pain effect, increasing acetylation at the Gad2 promoter and increasing its transcription.
Next, we examined Gad2 transcription in rats with spinal nerve ligation (SNL), another rodent model of chronic neuropathic pain that lasts for months 28 . We collected NRM tissues from rats with SNL and sham-operated control rats at 1 d (representing acute pain) and 21 d (representing prolonged pain) after surgery ( Fig. 4f) . We found that the acetylated H3 level in the Gad2 promoter showed no change at 1 d but was reduced at 21 d after surgery ( Fig. 4g) . Moreover, both GAD65 mRNA and protein levels were decreased at 21 d but not at 1 d after surgery ( Fig. 4g,h) . Thus, both prolonged sensitization of neuropathic pain and inflammatory hyperalgesia epigenetically reduce Gad2 transcription.
Histone hyperacetylation increases GABA synaptic function
As expected from the above results of pain-reduced GABA synaptic function by epigenetic hypoacetylation at Gad2, treatment with TsA or SAHA augmented GABA neurotransmission, increasing the mIPSC frequency in neurons from CFA-and saline-injected rats (Fig. 5a ). This suggests that GAD65 expression is important for GABA neurotransmission and that its epigenetic repression by persistent pain decreases (and its pharmacological augmentation by HDAC inhibitors enhances) GABA synaptic transmission.
Considering the nonselective, acetylation-promoting effects of HDAC inhibitors, we analyzed GABA IPSCs in the NRMs of Gad2 knockout mice. We found the slope of the IPSC input-output curve to be reduced in neurons from Gad2 −/− mice when compared with wildtype mice (Fig. 5b) . This indicates Gad2-deletion-induced reduction in GABA synaptic function, consistent with the effects of pain ( Fig. 2b) . Supporting a presynaptic function of GAD65, mIPSC frequency, but not amplitude, was lower in neurons from Gad2 −/− mice than in those from wild-type mice ( Fig. 5c,d) , indicating impaired presynaptic GABA release, also consistent with the effects of pain ( Fig. 2g-j) . Furthermore, in Gad2 −/− mice, both TsA and SAHA failed to increase mIPSC frequency ( Fig. 5c,d) , and the mIPSC amplitude was unaffected. Thus, it seems that HDAC inhibitors enhance GABA neurotransmission ( Fig. 5a ) by promoting histone acetylation at Gad2, as they lost this effect in Gad2 −/− mice.
In examining potential GAD67 roles in pain-reduced presynaptic GABA function despite its predominant cytoplasmic localization, we found that the acetylated H3 level in the three Gad1 (encoding GAD67) sequence regions we looked at was unchanged at 3 d after CFA injection ( Fig. 5e and Supplementary Fig. 1) . The GAD67 mRNA level was also unchanged. However, CFA produced a small but significant decrease in GAD67 protein expression ( Fig. 5e,f) . TsA increased GAD67 protein levels in CFA-and saline-injected rats at 3 d after injection ( Supplementary  Fig. 2 ). Thus, it seems unlikely that CFA has substantial effects on Gad1 transcription through histone acetylation, but cytosolic GAD67 may have some role in CFA-induced pain sensitization.
Histone hyperacetylation relieves pain
We examined the neuronal excitability of two previously characterized classes of NRM neurons: µ-opioid receptor (MOR)-lacking and MORexpressing cells 29 . The latter presumably comprises the descending pain-facilitatory system 19, 30 . We found that MOR-expressing cells, identified by hyperpolarization with the MOR agonist [d-Ala 2 , N-MePhe 4 , Gly-ol]-enkephalin (DAMGO) (1 µM) ( Fig. 5g) , had a larger number of depolarization-evoked action potentials in CFAinjected rats 3 d after injection than in control rats (Fig. 5g) . We did not observe this difference in cells lacking MOR ( Fig. 5h and  Supplementary Fig. 3) . Thus, the increased excitability of MORexpressing NRM cells may underlie the cellular mechanism for CFAinduced activation of descending pain facilitation.
To determine whether GAD65-promoting HDAC inhibitors could alleviate pain, we conducted behavioral experiments in vivo. TsA repeatedly (once a day for 4 d) infused into the NRM attenuated CFA-induced hyperalgesia in a dose-dependent manner, as did SAHA (Fig. 6a-c) . A single TsA infusion was ineffective (data not shown). Repeated TsA pretreatment before CFA injection failed to alter the effect of CFA at 4 h after injection (Fig. 6d) , which excludes an effect of TsA on the acute effect of CFA.
Histone-hyperacetylation-induced pain relief requires GAD65
We obtained additional evidence supporting the role of GAD65 in the pain mechanism from behavioral experiments on Gad2 −/− mice. Compared to wild-type mice, Gad2 −/− mice had a lower baseline pain threshold, indicating a sensitized basal pain state (basal hyperalgesia) ( Fig. 6e) , consistent with CFA-induced hyperalgesia through epigenetic a r t i c l e s inhibition of GAD65 expression. Furthermore, in Gad2 −/− mice, similar NRM infusions of TsA could no longer ameliorate the sensitized pain behavior (Fig. 6e) , further supporting the role of GAD65 in histonehyperacetylation-induced pain relief. To determine how Gad2 −/− mice might respond to CFA differently, we treated them with CFA and found that, in addition to the basal hyperalgesia seen in Gad2 −/− mice, CFA induced further pain sensitization to a level similar in amplitude to that in wild-type mice at 1 d after treatment (Fig. 6f) . This indicates that this acute CFA effect is independent of GAD65 and may be mediated by as-yet unidentified mechanisms. Notably, at 3 d after injection, the amplitude of hyperalgesia remained unchanged in wild-type mice but was partially recovered in Gad2 −/− mice (Fig. 6f) . The underlying mechanisms of this effect remain to be investigated. Next, we reasoned that, if GAD65-suppression-induced loss of GABA synaptic inhibition contributes to pain hypersensitivity, pharmacologically promoting GABA inhibition under those conditions should alleviate hyperalgesia. As predicted, in rats at 3 d after CFA injection, acute NRM infusion of the GABA A receptor agonist muscimol induced an antinociceptive effect (Fig. 6g) . Therefore, like histone-hyperacetylation-mediated upregulation of GAD65 transcription and GABA function, pharmacological activation of inhibitory GABA function also can relieve pain.
Depression and proinflammatory cytokines
Chronic pain is often associated with psychophysiological disorders such as depression 31 . To determine the potential effects of depression, we treated SNL rats and sham-operated rats with the antidepressant drug fluoxetine for 21 d, a treatment that reverses depressive behavior in rodents 32 . We found that fluoxetine had no effect on the SNLreduced expression of NRM GAD65 protein (Supplementary Fig. 4) , thus probably excluding a general effect of depression on GAD65 expression in the NRM.
CFA is known to release pain-facilitating proinflammatory cytokines, including interleukin 1 (IL-1) 33 . We examined the effect of IL-1β on NRM GAD65 expression and pain threshold. IL-1β infused into the NRM decreased the pain threshold in naive rats acutely for about 4 h (Fig. 6h) . Co-infusion of IL-1β and the IL-1 receptor antagonist IL-1Ra largely blocked the IL-1β effect. However, unlike CFA-induced hyperalgesia, repeated NRM infusions of IL-1β did not produce lasting hyperalgesia over 3 d, although its acute effect remained (Fig. 6h) . In NRM tissues from rats treated repeatedly with IL-1β, we found no change in GAD65 protein (Fig. 6i,j) . Furthermore, repeated NRM infusions of IL-1Ra failed to block the CFA-induced reduction in GAD65 (Fig. 6i,j) . These results indicate that, although proinflammatory cytokines are important in chronic pain development 33, 34 , NRM IL-1 is unlikely to have a major role in CFA-induced modulation of GAD65 expression and related pain mechanisms.
DISCUSSION
In rat and mouse models of chronic pain, we have shown that persistent pain, but not acute pain, epigenetically suppresses the transcription of Gad2 and consequently causes impaired inhibitory function of GABAergic synapses in central pain-modulating neurons, contributing to the development of persistent pain sensitization. These results are supported by observations in Gad2 −/− mice showing impaired GABA synaptic function in the same neurons and having sensitized pain behavior. In addition, histone hyperacetylation overcomes these molecular and synaptic changes by promoting Gad2 transcription and GABAergic synaptic function, thereby relieving the sensitized behavior of persistent pain. Chronic pain involves altered expression of many genes through unknown mechanisms 35 . In drug addiction, histone H3 and H4 acetylation modulates the expression of several genes that regulate transcription, including Cdk5, Fos, Creb and ∆FosB 8 . In nerve-injury-induced hypoesthesia, C-fiber dysfunction is reportedly mediated by epigenetic upregulation of the transcriptional repressor neuron-restrictive silencer factor, but pain sensitization does not seem to involve upregulation of this factor 17 . Notably, HDAC inhibitors reduce inflammatory pain by upregulating spinal metabotropic glutamate 2 receptors 16 . The present study identifies Gad2 as an important target gene of histone modifications induced by persistent pain conditions, providing a potential epigenetic mechanism for the development of chronic pain.
GAD65 is preferentially targeted to presynaptic terminals of central neurons for synthesis of GABA within synaptic vesicles and is required for active GABA synaptic release 23, 24, 36 . Impaired GABA release would cause loss of GABAergic inhibition, leading to neuronal hyperactivation. For instance, nerve injury induces a loss of GABA inhibition in spinal neurons, and enhancing GABA synaptic inhibition is effective in relieving injury-induced pain [37] [38] [39] . Our results from rats and GAD65-deficient mice suggest that the persistent pain induced by inflammation and neuropathy downregulates GAD65 transcription, causing impairment of GABA synaptic inhibition in the NRM and increasing the excitability of presumably pain-facilitating neurons. This is in line with recent reports that Gad2 −/− mice show sensitized pain behavior 40 and that viral delivery of Gad2 produces orofacial analgesia 41 . Given the multifaceted mechanisms of chronic pain, it is likely that other genes in addition to Gad2 also are targets of chronic pain-induced chromatin remodeling. This probably accounts for our observation of increased global histone acetylation by CFA, indicating increased activities of other genes that remain to be investigated. Although the pain-induced changes in GAD65 transcription and GABA synaptic function indicate a likely neuronal locus, further studies are necessary to verify its localization within the nucleus of central neurons for pain-induced histone modification.
GAD67 is a GABA-synthesizing enzyme for cytoplasmic GABA and its tonic release from neurons 23 . Our data show a major role of presynaptic GAD65 in the pain mechanism, but this does not preclude a role for cellular GAD67, particularly in pain-induced adaptive changes in neuronal excitability for sensitized pain behaviors. Although our results do not indicate pain-induced epigenetic modulation of Gad1 through histone acetylation, GAD67 could participate in pain mechanisms by decreasing tonic inhibition among neurons through reducing the levels of cellular GABA, by reducing synaptic GABA through presynaptic effects or by compensatory changes in response to GAD65 deficiency. The detailed mechanisms by which GAD67 might play a role in pain warrants further study. a r t i c l e s How functionally distinct populations of NRM neurons adapt to chronic pain conditions and mediate sensitized pain behaviors in chronic pain remains unclear. Under normal conditions, opioids produce analgesia partly by reducing basal GABA transmission in NRM neurons, thereby activating the descending pain-inhibition system 29, 42 . Consistent with this, GABA A receptor antagonists applied to the NRM induce antinociception, whereas GABA A receptor agonists produce pain sensitization 43, 44 . However, under chronic pain conditions, considerable adaptive changes may have occurred both in GABA input activities on different classes of NRM neurons and in GABA A receptor properties. Our results indicate that the paininduced impairment of GABA synaptic inputs may preferentially affect and consequently hyperactivate MOR-expressing neurons. Activation of this neuron class presumably facilitates spinal pain transmission 29, 30 , contributing to sensitized pain behaviors. A paininduced decrease in GABA neurotransmission has also been reported recently in amygdala neurons from a rat model of arthritic pain 45 . This GABA-impairment-induced pain sensitization is further supported by our behavioral results that enhancing GABA inhibition by activating NRM GABA A receptors produces an antinociceptive effect. Detailed molecular and cellular adaptations in GABA and glutamate synapses under chronic pain conditions are subjects of ongoing research.
Proinflammatory cytokines, released into the peripheral and central circulation by immune cells and glia in response to tissue inflammation and trauma, cause augmented pain 33, 34 , but the underlying cellular and molecular mechanisms of this process remain unclear, particularly in chronic pain states. Proinflammatory cytokines may contribute to the development of chronic pain by sustained release from their sources and by their sensitized signaling mechanisms in nociceptors and central neurons to augment pain responses after healing. Our observations of both the relatively acute hyperalgesic effect of IL-1β and the inability of repeated IL-1β administration in the NRM to change GAD65 expression indicate that this proinflammatory cytokine, at least in the NRM, is not substantially involved in the GAD65-mediated pain mechanisms that mediate prolonged pain behaviors induced by SNL and CFA.
A current common clinical problem is the transition from analgesicresponsive acute pain to chronic pain, of which some types are poorly responsive to currently available analgesics and often lead to longterm neuropsychiatric disorders such as depression, stress and drug addiction 10, 12, 46, 47 . Although multiple forms of neuronal plasticity have been identified for the pathogenesis of chronic pain 13 , the mechanisms underlying this crucial transition from acute pain to chronic pain remain poorly understood. Our findings of chromatin modifications emerging only days after pain development indicate that the epigenetic mechanism of Gad2 modulation might underlie the persistent phase of these pain conditions, and this, together with changes in the expression of other genes, could be an important initial step in the transition that leads to the development of chronic pain and associated disorders. In this regard, drugs such as HDAC inhibitors that overcome the effects of persistent pain on the output activities of Gad2 and other target genes may serve as a new promising class of analgesics 48 , as they could collectively block the upstream cause of pain-induced alterations that lead to multiple system malfunctions and clinical symptoms during chronic pain development.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
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